Bridging the gap between science and society: long-term effects of the Healthy Lifestyle Community Programme (HLCP, cohort 1) on weight and the metabolic risk profile: a controlled study

Corinna Anand,1,2 Ragna-Marie Kranz,2 Sarah Husain,2 Christian Koeder,2 Nora Schoch,2 Dima-Karam Alzughayyar,2 Reinhold Gellner,1 Karin Hengst,1 Heike Englert2

ABSTRACT

Background The potential of adopting a healthy lifestyle to fight non-communicable diseases (NCDs) is not fully used. We hypothesised that the Healthy Lifestyle Community Programme (HLCP, cohort 1) reduces weight and other risk markers compared with baseline and control.

Methods 24-month, non-randomised, controlled intervention trial. Intervention: intensive 8-week phase with seminars, workshops and coaching focusing on a healthy lifestyle (eg, plant-based diet, physical activity, stress management) and group support followed by a 22-month alumni phase. Weight reduction as the primary outcome and other NCD risk parameters were assessed at six time points. Participants were recruited from the general population. Multiple linear regression analyses were conducted.

Results 143 participants (58±12 years, 71% female) were enrolled (91 in the intervention (IG) and 52 in the control group (CG)). Groups’ baseline characteristics were comparable, except participants of IG were younger, more often females, overweight and reported lower energy intake (kcal/day). Weight significantly decreased in IG at all follow-ups by −1.5 ± 1.9 kg after 8 weeks to −1.9 ± 4.0 kg after 24 months and more than in CG (except after 24 months). Being male, in the IG or overweight at baseline and having a university degree predicted more weight loss. After the intervention, there were more participants in the IG with a ‘high’ adherence (+12%) to plant-based food patterns. The change of other risk parameters was most distinct after 8 weeks and in people at elevated risk. Diabetes-related risk parameters did not improve.

Conclusion The HLCP was able to reduce weight and to improve aspects of the NCD risk profile. Weight loss in the IG was moderate but maintained for 24 months. Participants of lower educational status might benefit from even more practical units. Future interventions should aim to include more participants at higher risk.

Trial registration number DRKS00018821.

What this paper adds

⇒ Insights in the effects of comprehensive lifestyle programs as measures to prevent and treat non-communicable diseases.
⇒ Overview of the design and methodology of real-world community approaches.
⇒ Discussion about target group-specific content of lifestyle educational programs.

BACKGROUND

Avoiding obesity would protect people from losing disease-free years owing to lifestyle-related non-communicable diseases (NCDs), like cardiovascular diseases and type 2 diabetes.1 Moreover, the COVID-19 pandemic has highlighted that NCDs are also a risk factor for a serious course of infectious diseases2 and can therefore be an immense burden to personal and public health. However, the immense potential of a healthy lifestyle to prevent, arrest or even reverse NCDs3–5 is still not fully embraced by patients and healthcare providers.

There is general consensus how a healthy lifestyle is characterised: (1) A more plant-based diet,1 5 6 (2) regular exercise6 and (3) managing stress.7 8 Yet, neither are most people aware how big their own behaviours and choices influence risk, nor are they adequately educated how to change their lifestyle accordingly.9 This is especially true for men and people of low socio-economic status, who typically have a lower level of health literacy, that is, they lack knowledge and resources to promote their own health and attend health education programmes less frequently.10–12
Though lifestyle interventions do report improvement of overweight (OW) and other risk parameters, effects are heterogeneous. Lifestyle interventions that meet the complexity of sustainable behavioural change and, at the same time, reduce complexity for participants wherever possible, are urgently needed. As real-world lab approaches intend to cocreate interventions with local stakeholders and overcome the artificiality of the lab setting, they seem suitable to transfer evidence-based knowledge and skills about a healthy lifestyle from science to society.

Research objective
This study examined if the Healthy Lifestyle Community Programme (HLCP, cohort 1) was able to improve the metabolic risk profile of NCDs in the long-term through the adoption of health behaviour and lifestyle changes.

Our primary hypothesis was that participants of the intervention group (IG) would reduce their weight significantly after 8 weeks, and again at 6, 12, 18 and 24 months compared with baseline and significantly more than participants of the control group (CG). We secondarily hypothesised that in the IG important risk markers for NCDs, that is, waist circumference (WC), blood parameters (total, low-density lipoprotein and high-density lipoprotein cholesterol (total-C, LDL-C, HDL-C), triglycerides (TG), fasting glucose (FG), glycated haemoglobin A1c (HbA1c), fasting insulin (FI), insulin sensitivity via Homeostasis Model Assessment-insulin resistance (HOMA-IR)) and vital parameters (systolic and diastolic blood pressure (SBP, DBP)) would improve after 8 weeks, and again after 6, 12, 18 and 24 months compared with baseline and more than CG.

METHODS
Study design
We conducted a non-randomised, controlled intervention trial with a duration of 24 months (see figure 1). As with all lifestyle interventions, blinding of participants or instructors was not possible (as described previously). Staff performing laboratory assessments were unaware of group allocation.

Study population
Sample size calculation
The sample size was calculated with the kind support from the Institute for Biometry and Clinical Research in Muenster, Germany. Six confirmatory tests were planned to prove the effectiveness of the intervention in terms of weight reduction. Assumed effect sizes for sample size calculation were obtained from pilot study data with a prototype version of the lifestyle programme. A total of 84 subjects was calculated (56 in IG, 28 in CG), to obtain a power of 0.8 at a global significance level of 0.05. Expecting a drop-out of at least 10%, we aimed for 92 participants. In order to test the HLCP in the real-world lab and to allow engaged community members to participate, exceeding this minimum sample size was tolerated.

Recruitment
Participants of the IG and CG were recruited from the general population in rural Germany and to ensure that
they came from different communities, they were recruited separately from a ‘intervention municipality’ and a ‘control municipality’. However, due to our complex real-world approach, which requires involvement of local stakeholders in the planning stage and before recruitment was initiated, it was not possible to cluster randomise. Notably, we included not only participants at a high risk for NCDs but also health-conscious persons. In the IG, they were desirable role models (ie, peer support). In the CG, they insured comparability of the groups.

Inclusion criteria
Participants ≥18 years, who were capable of understanding the study content were included.

Participants’ flow diagram
A participants’ flow diagram following the Consolidated Standards of Reporting Trials structure shows the study process from enrolment to analysis in figure 2. Sample sizes are provided throughout, and qualitative reasons for dropouts and losses to follow-up are given wherever possible. A total of n=143 participants were enrolled (n=91 in IG and n=52 in CG, respectively). 57% of the IG (n=52) and 52% (n=27) of the CG finished the study.

Health checks
Data were collected at six health checks starting with the baseline assessment in April in IG and October 2017 in CG, respectively. Follow-ups were assessed at 8 weeks, that is, after the intensive phase of the HLCP, and at 6, 12, 18 and 24 months during a 22-month alumni phase in the IG (see figure 1).

Anthropometric and vital parameters
Body weight was determined by calibrated body scales, height by self-report and body mass index (BMI; kg/m²)
was calculated, accordingly. Waist circumference (WC) was determined according to the WHO protocol.\(^1\) SBP, DBP at rest were determined in duplicate by means of a calibrated blood pressure metre.

**Blood parameters**

Blood sampling was done in the morning in the fasted state. Metabolic parameters in venous blood (serum) were assessed to establish the risk profile of participants and all analyses were conducted at the University Hospital of Muenster. For lipids, the following reference values were considered optimal:\(^9\) total-C levels $\leq 200$ mg/dL, LDL-C $<130$ mg/dL, HDL-C for women $>45$ mg/dL and for men $>40$ mg/dL, respectively, TG $<150$ mg/dL. FG $>126$ mg/dL or HbA1c $>6.5\%$ were diagnostic of diabetes, FG from 100 to $\leq 125$ or HbA1c from 5.7 to $\leq 6.5\%$ for pre-diabetes, accordingly.\(^10\) FI was assessed and HOMA-IR was calculated.\(^11\) A cut-off of 2.5 was used to differentiate good and impaired insulin sensitivity.\(^12\)

**Dietary assessment and questionnaires**

Participants filled out weighed food records on three consecutive days (including one weekend day).\(^2\) Nutritional intake was computed using the diet software EBIISpro 2016 (Dr. J. Erhart, University of Hohenheim, Stuttgart, Germany). To measure adherence to a plant-based diet, a pro-vegetarian food score (ranging from 12 to 60) was calculated and categories of adherence were built (very low, low, moderate, high and very high adherence).\(^13\)

Validated questionnaires to assess other health parameters (eg, stages of behavioural change,\(^14\) physical activity,\(^15\) and perceived stress\(^16\)) were assessed among others and results will be published separately.

**Lifestyle intervention**

The intensive 8-week phase of the HLCP consisted of 14 consecutive seminars (2 hours each, ie, 28 seminar hours in total). Topics included prevention of NCDs, characteristics of a healthy diet, physical activity and stress management, emphasising community support and the chances of behaviour change. Dietary recommendations were to move towards a healthy plant-based diet, high in vegetables, fruits, whole grains, legumes and plant oils, low in meat (especially red and processed meat products), high fat dairy and highly processed foods, for example, refined grains and sugar-sweetened beverages. Evidence-based content about a healthy lifestyle\(^1-7\) was communicated vividly including study materials, for example, workbook, recipe booklet. Gender-specific topics, that are considered sensitive (ie, prostate cancer or postmenopausal weight gain), were discussed in single-gender sessions. Practical units (eg, cookery demonstrations and guests’ sessions of local practitioners) were embedded to the seminars and 8 additional workshops (eg, healthy shopping, stress relieve; ~20 participants each; ~2 hours duration) were offered to improve practical skills. In two individual health coaching at baseline and after 8 weeks, results of the health checks and personal goals were discussed. The subsequent 22-months alumni phase consisted of monthly meetings (2 hours each) in which contents of the intensive phase were refreshed and group support was strengthened.

**Control group**

The CG did not receive any intervention, but participants were informed about health checks results (ie, they could seek medical advice if needed). CG was offered to participate in a subsequent HLCP after completion of the study.

**Statistics**

All data were analysed according to a predefined plan and all available cases were used. Normality was tested using the Shapiro-Wilk test and judged by histograms.

To compare IG and CG, independent t-test was used for normally distributed continuous variables and Mann-Whitney U test as its non-parametric alternative. Comparisons of dichotomous categorical variables were tested by Fisher’s exact test. Within group comparisons for normally distributed continuous variables were performed by one sample t test or Welch test. Alternatively, the non-parametric Wilcoxon signed-rank test was performed. All tests were two sided.

Multiple linear regression (MLR) models were used to estimate were used to estimate the effect of the intervention on weight change. Variables found to be associated with weight change were added as covariates (in addition to the group variable) to the MLR using a forward-backward selection approach. Regression models that were statistically significant ($p \leq 0.05$) with the highest corrected $R^2$ and lowest number of covariates were selected. For all secondary outcome parameters MLR was used to explore the effect of the intervention, adjusting for sex, the baseline value and the baseline risk status of the respective variable. In all models, residuals have been checked for normality.

To evaluate the effect of the intervention on subgroup, the cohort was divided retrospectively (eg, gender and weight status). Values of $p \leq 0.05$ were considered significant, and are to be understood confirmative for the six hypotheses regarding weight change as the primary outcome, and exploratory\(^2\) for secondary outcome parameters.

Statistical analyses were performed using SPSS V.25 for Windows (SPSS).

**RESULTS**

**Baseline characteristics**

Baseline demographic characteristics of IG and CG are shown in table 1. We observed no significant differences in most parameters, but participants of IG were younger, more often female and OW and reported lower energy intake than in CG.

21% and 29% in IG and CG, respectively, held a university degree (UD). Metabolic risk profiles regarding blood and vital parameters were comparable in both groups;
Table 1 Baseline characteristics by study group (n=143)

|                          | Intervention | Control | P value |
|--------------------------|--------------|---------|---------|
| Sociodemographics        |              |         |         |
| Age, mean±SD             | 56±10        | 62±14   | <0.001* |
| Female, n (%)            | 70 (77)      | 31 (57) | 0.024†  |
| Married/ in relationship, n (%) | 73 (81) | 39 (80) | 0.925†  |
| Participated with family, n (%) | 26 (29) | 15 (29) | 0.852†  |
| Men                      | 12 (57)      | 7 (33)  | 0.215†  |
| Women                    | 14 (20)      | 8 (26)  | 0.603†  |
| Education, n (%)         |              |         | 0.266†  |
| Lower secondary school   | 21 (23)      | 13 (27) |         |
| Higher secondary school  | 29 (32)      | 17 (35) |         |
| High school              | 21 (23)      | 5 (10)  |         |
| University               | 19 (21)      | 14 (29) |         |
| Anthropometrics           |              |         |         |
| Weight (kg), mean±SD     | 85±19        | 80±18   | 0.113‡  |
| BMI (kg/m²), mean±SD     | 28.7±5.4     | 27.0±6.5| 0.020‡  |
| Waist circumference (cm), mean±SD | 98±14 | 98±17 | 0.770‡  |
| Participants with overweight/ obesity§, n (%) | 67 (74) | 28 (55) | 0.015†  |
| LDL/C (mg/dL), mean±SD   | 125±36       | 127±41  | 0.836‡  |
| Participants with elevated risk¶, n (%) | 36 (46) | 25 (49) | 0.867†  |
| LDL/HDL ratio, mean±SD   | 2.2±1.0      | 2.5±1.1 | 0.117*  |
| HDL-C (mg/dL), mean±SD   | 65±19        | 56±18   | 0.038*  |
| Participants with elevated risk‖, n (%) | 7 (9) | 13 (25) | 0.010†  |
| Total-C (mg/dL), mean±SD | 196±33       | 193±46  | 0.692*  |
| Participants with elevated risk**, n (%) | 39 (48) | 23 (45) | 0.858†  |
| LDL-C (mg/dL), mean±SD   | 125±36       | 127±41  | 0.836‡  |
| Participants with elevated risk††, n (%) | 36 (46) | 25 (49) | 0.867†  |
| HDL-C (mg/dL), mean±SD   | 65±19        | 56±18   | 0.038*  |
| Participants with elevated risk‖‖, n (%) | 7 (9) | 13 (25) | 0.010†  |
| TG (mg/dL), mean±SD      | 121±69       | 125±76  | 0.612*  |
| Participants with elevated risk§§, n (%) | 17 (21) | 11 (22) | 1.000†  |
| Diabetic parameters      |              |         |         |
| FG (mg/dL), mean±SD      | 95±15        | 97±26   | 0.032*  |
| Participants with elevated risk¶¶, n (%) | 20 (25) | 25 (49) | 0.004†  |
| HbA1c (%), mean±SD       | 5.4±0.6      | 5.6±0.5 | 0.001*  |
| Participants with elevated risk***, n (%) | 14 (18) | 17 (33) | 0.057†  |
| Fasting insulin (µU/mL), mean±SD | 10±6 | 11±8 | 0.760*  |
| HOMA-IR, mean±SD         | 2.4±1.7      | 2.8±2.9 | 0.571*  |
| Participants with impaired insulin sensitivity†††, n (%) | 28 (37) | 22 (43) | 0.579†  |
| Vital parameters         |              |         |         |
| SBP (mm Hg), mean±SD     | 136±20       | 131±20  | 0.148*  |
| Participants with elevated risk‡‡‡, n (%) | 70 (79) | 36 (71) | 0.310†  |
| DBP (mm Hg), mean±SD     | 86±1         | 81±9    | 0.002*  |
| Participants with elevated risk§§§, n (%) | 64 (72) | 31 (61) | 0.192†  |
| Energy intake (kcal/day), mean±SD | 1815±424 | 2028±450 | <0.001* |

Continued
except for HDL-C, diabetic parameters (FG, HbA1c) and DBP, which were better in IG.

**Primary confirmatory analyses of weight change**
Changes of weight in IG and CG compared with baseline, between groups and separated by sex and risk groups, are presented in table 2.

Weight significantly decreased in IG after 8 weeks, 6, 12, 18 and 24 months compared with baseline and significantly more than in CG—except for after 24 months (see figure 3). BMI followed the same pattern.

Analyses separated by BMI group at baseline indicated, that normal weight (NW, BMI<25 kg/m²) and (OW, BMI ≥25 kg/m²) participants lost more weight in IG than in CG after 8 weeks (p=0.008 and p=0.016, respectively). In IG, OWs also decreased weight more than NWs after 8 weeks (p=0.029) and stayed below baseline levels at all follow-ups (p<0.001 after 8 weeks to 18 months and p=0.002 after 24 months).

Interestingly, participants with a UD did not only maintain weight loss over time but their weight also decreased further up to −6% after 18 and 24 months, resulting in higher weight loss than in other education subgroups (p=0.006, p=0.004 and p=0.003 after 12, 18 and 24 months, respectively) where it stayed on a lower level but did not decrease noteworthy after an initial drop after 8 weeks.

Since a weight loss of 5%–10% is considered to be a doable long-term goal,29 we tested, whether it could be achieved by the HLCP. In the IG, 37% (n=29) of the participants lost >5% of their baseline weight during the study course of 2 years, and 14% (n=7) in the CG, accordingly (p=0.008).

**Regression analysis**
MLR analyses identified being in the IG, male and OW at baseline as well as the male-by-IG interaction as predictors for weight loss after 8 weeks (online supplemental table S-1). This means, as figure 4 shows: NW and OW men (dark grey bars) in the IG, lost more weight than NW and OW women (dark grey striped bar) and more than NW and OW men of CG (grey bar). NW and OW women in the IG, however, lost comparably as much weight as men of CG and even less than women of CG (grey striped bar).

Being male (p=0.040) and OW (p=0.016) also predicted weight loss after 18 months (adjusted for male by participating with/without family).

In the MLR, having a UD turned out to be a predictor for weight loss after 6 (p=0.027), 12 (p=0.080) and 18 months (p=0.040), and the UD-by-IG interaction after 24 months (p=0.069 (online supplemental table S-1)). Consistently with the results of the descriptive analyses, being OW at baseline influenced weight loss not only after 8 weeks (p=0.028) but also after 18 months (p=0.016). The effect of the IG alone on weight loss, however, was not significant (p>0.05) at follow-ups from 6 months onwards.

---

**Table 1** Continued

| Adherence to provegetarian food pattern, n (%) | Intervention | Control | P value |
|----------------------------------------------|--------------|---------|---------|
| Adherence to provegetarian food pattern, n (%) | Intervention | Control | P value |
| Very low | 10 (12) | 6 (13) | 0.964† |
| Low | 21 (26) | 10 (22) | |
| Moderate | 34 (42) | 20 (44) | |
| High | 11 (13) | 7 (16) | |
| Very high | 6 (7) | 2 (4) | |

Bold p-values ≤0.05
* Mann-Whitney U test.
† Fisher's exact test.
‡ Two-sample t-test.
§ BMI ≥25 kg/m².
¶ ≥102 cm and ≥88 cm for men and women, respectively.
** ≥200 mg/dl
†† ≥130 mg/dl
‡‡ ≥40 and 45 mg/dL for men and women, respectively.
§§ ≥150 mg/dl
¶¶ ≥100 mg/dl
*** ≥5.7%
††† HOMA-IR ≥2.5.
‡‡‡ ≥120 mm Hg.
§§§ ≥80 mm Hg.
¶¶¶ Adherence according to points of the provegetarian food score: very low (<30 points), low (30–34 points), moderate (35–39 points), high (40–44 points) and very high (>44 points).24

BMI, body mass index; DBP, diastolic blood pressure; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HOMA-IR, Homeostasis Model Assessment-insulin resistance; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides; Total-C, total cholesterol.
### Table 2  Change of weight in intervention and control group according to relevant subgroups 8 weeks, 6, 12, 18 and 24 months after baseline, all values are mean±SD

|                  | Intervention | Change after | Control | Change after |
|------------------|--------------|--------------|---------|--------------|
|                  | Initial value at baseline | 8 weeks | 6 months | 12 months | 18 months | 24 months | Initial value at baseline | 8 weeks | 6 months | 12 months | 18 months | 24 months |
| **Weight (kg)**  |              |             |         |            |            |           |              |         |            |            |            |           |
| **Men**          | 97.3±19.1   | 97.3±19.1   | −2.7±2.6*‡§ | −2.6±4.5* | −2.6±4.5* | −2.6±4.5* | 89.5±20.5 | −0.2±1.8 | −0.9±2.3 | −0.7±2.7 | −0.8±2.9 | −1.0±5.4 |
| **Women**        | 80.9±17.6‡ | 80.9±17.6‡ | −1.2±1.5**‡ | −0.9±2.8* | −0.9±2.8* | −0.9±2.8* | 72.6±13.3 | −0.3±1.7 | −0.2±1.6 | −0.2±2.4 | 0.0±2.5 | −0.7±5.1 |
| **NW**           | 66.3±17.7   | 66.3±17.7   | −0.9±1.1‡   | −0.5±2.1  | −1.7±1.8*‡ | −1.6±1.5† | 66.9±8.8  | 0.1±1.1  | −0.8±1.4 | −0.3±1.6 | 0.3±1.6  | 0.1±2.3  |
| **OW**           | 91.1±17.2¶  | 91.1±17.2¶  | −1.8±2.0**‡¶ | −1.7±3.7*¶ | −2.6±3.7** | −2.2±4.5* | 89.9±17.9¶ | −0.6±2.1 | −1.0±2.3 | −0.7±3.4 | −1.0±3.5 | −1.6±6.6 |
| **With fam.**    | 88.8±21.4   | 88.8±21.4   | −1.1±1.5†   | −0.7±2.7  | −1.6±3.1  | −0.6±3.8  | 77.6±19.5 | 0.3±1.3  | 0.1±1.6  | 0.2±1.9  | 0.4±1.7  | 0.2±1.7  |
| **Without fam.** | 83.1±17.6   | 83.1±17.6   | −1.7±2.0**‡ | −1.6±3.6**‡ | −2.8±3.7**‡ | −2.5±3.9* | 80.3±18.2 | −0.5±1.8 | −0.7±2.1 | −0.8±2.8 | −0.6±3.0 | −0.9±5.4 |
| **No UD**        | 84.2±19.7   | 84.2±19.7   | −1.4±1.8**‡ | −1.1±3.2* | −1.7±2.9* | −1.4±3.5* | 78.6±17.5 | −0.3±2.0 | −0.8±2.1 | −0.8±2.7 | −0.5±2.8 | −0.5±5.2 |
| **UD**           | 86.7±15.2   | 86.7±15.2   | −1.9±2.2**‡ | −2.6±3.9*‡ | −4.6±3.7**‡|$ | −5.3±3.8*‡|$ | 78.3±16.9 | −0.1±0.9 | 0.2±1.4  | 0.4±2.0  | 0.2±2.4  | −2.0±5.1 |

Due to large amount of data, numbers are shown with only one decimal and sample sizes are left out for better readability. A full version of the table, including additional parameters, is provided in online supplemental table S-3.

‡P<0.05 for between group comparison to control
‡‡P<0.001 for between group comparison to control
§P<0.05 for comparison of men and women
¶P<0.05 for comparison to NW
†P<0.05 for comparison to came with family
$P<0.05 for comparison to no UD

*P<0.05, **p<0.01, for within group comparison to baseline.

fam, family; NW, normal weight; OW, overweight; UD, university degree.
Secondary exploratory analyses of anthropometric, blood and vital parameters and dietary intake

The changes of metabolic parameters did not follow a clear pattern. They were most distinct after 8 weeks (ie, the intensive phase of the HLCP) and improved especially in people at elevated risk (eg, total-C, TG, SBP, DBP). For complete presentation of blood parameters, WC and additional subgroup analyses, see online supplemental figure S-2 and online supplemental table S-3.

Notably, FG increased in IG compared with baseline after 6 (p=0.031), 12, 18 and 24 months (for all p<0.001). P values suggest a relevant difference in FG change between the IG and CG after 8 weeks (p<0.001), 6 months (p<0.05), 12 months (p<0.05), 18 months (p<0.05). CG, control group; IG, intervention group.

Regression analyses

MLR, adjusting for sex, baseline value and risk status of the respective variables, revealed a significant impact of the HLCP at different time points on an improvement of BMI, total-C, LDL-C, HDL-C and DBP and on an increase of WC and all diabetic parameters (table 3). As described above, most significant effects appeared after 8 weeks. The increase of FG stayed distinct (p<0.001 after 8 weeks, 12 and 18 months and p=0.001 after 6 and 24 months) even after adjusting for the baseline values and risk group.

DISCUSSION

In summary, the HLCP, cohort 1 moderately reduced weight and improved some parameters of the risk profile for metabolic NCDs, such as total and LDL cholesterol.

Weight loss in the IG was moderate but comparable with other interventions.30 Studies with a stricter diet regimen show more distinct results, for example, a vegan healthy diet with a weight loss of −6.5 kg after 16 weeks.31 Yet, variability in weight outcomes among participants of lifestyle interventions is high14 and smaller effects were expected due to the real-world approach—as opposed to controlled study lab conditions of regular dieting studies. Still, 37% of the participants in the HLCP were able to reduce >5% of their baseline weight. Since combined interventions that do not only focus on diet alone have been shown to be more effective for long-term weight loss,32 a holistic approach seems suitable for a heterogeneous communities despite smaller effects.

Participants with a UD lost more weight (up to −5.7±3.5 kg after 18 months), suggesting that knowledge transfer was emphasised too strongly for participants of lower educational status. Therefore, we suggest even more practical units and simplified dietary rules—as we modified in subsequent HLCPs (cohort 217 and 3 (unpublished data)).

Figure 3 Boxplots of weight change (kg) in intervention (left, dark grey) and control group (white) after 8 weeks, 6, 12, 18 and 24 months after baseline (baseline values in intervention group: 85±19 kg, in control group: 80±18 kg). Differences to baseline were significant in IG after 8 weeks to 18 months (p<0.001) and 24 months (p=0.05). Differences between IG and CG were significant after 8 weeks (p<0.001), 6 months (p<0.05), 12 months (p<0.05), 18 months (p<0.05). CG, control group; IG, intervention group.

Figure 4 Weight loss after 8 weeks in intervention and control group according to sex and weight status at baseline; adjusted for age, participating with/without family interaction and the group-participating with/without family interaction (R²=0.216, p=0.001).
### Table 3
Effect of group (Ref. intervention group) on the metabolic risk profile (adjusted for sex, baseline values and risk group at baseline of the respective variable); forced enter approach

|                        | Change after 8 weeks |       |       |       |       | Change after 6 months |       |       |       |       | Change after 12 months |       |       |       |       | Change after 18 months |       |       |       |       | Change after 24 months |       |       |       |       |       |
|------------------------|----------------------|-------|-------|-------|-------|------------------------|-------|-------|-------|-------|------------------------|-------|-------|-------|-------|------------------------|-------|-------|-------|-------|------------------------|-------|-------|-------|-------|------------------------|-------|-------|
| **Anthropometrics**    |                      | β    | SE    | P     | R²    | β            | SE    | P     | R²    | β            | SE    | P     | R²    | β            | SE    | P     | R²    | β            | SE    | P     | R²    | β            | SE    | P     | R²    | β            | SE    | P     | R²    |
| BMI (kg/m²)            | −0.39                | 0.12  | 0.002 | 0.094 | 0.04 | −0.26        | 0.22  | 0.229 | 0.030 | −0.66        | 0.23  | 0.005 | 0.086 | −0.71        | 0.30  | 0.021 | 0.080 | −0.38        | 0.36  | 0.299 | 0.067 | 1.91        | 1.21  | 0.118 | 0.065 |
| WC (cm)                | 2.00                 | 0.89  | 0.027 | 0.049 | —     | 2.01         | 1.05  | 0.059 | 0.023 | −0.28        | 1.07  | 0.797 | −0.055 | −0.11        | 1.19  | 0.928 | 0.012 | 1.91        | 1.21  | 0.118 | 0.065 | 1.91        | 1.21  | 0.118 | 0.065 |
| **Blood parameters**   |                      |       |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |
| **Lipids**             |                      |       |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |
| Total-C (mg/dL)        | −21.94               | 4.81  | 0.000 | 0.316 | —     | −11.42       | 8.44  | 0.180 | 0.061 | −12.24       | 4.84  | 0.013 | 0.087 | −7.16        | 5.04  | 0.160 | −0.26 | −1.05        | 6.25  | 0.867 | 0.038 | −0.71        | 5.04  | 0.160 | −0.26 |
| LDL-C (mg/dL)          | −19.10               | 4.40  | 0.000 | 0.252 | —     | −13.37       | 4.51  | 0.011 | 0.241 | −10.87       | 4.16  | 0.004 | 0.142 | −8.84        | 4.59  | 0.059 | 0.007 | −2.86        | 5.97  | 0.635 | 0.088 | −11.42       | 5.04  | 0.160 | −0.26 |
| HDL-C (mg/dL)          | −6.39                | 1.61  | 0.000 | 0.253 | —     | −3.72        | 2.14  | 0.085 | 0.162 | −2.14        | 1.83  | 0.246 | −0.055 | 3.58         | 2.39  | 0.138 | 0.035 | 3.21         | 2.18  | 0.146 | 0.080 | −0.28        | 1.07  | 0.797 | −0.055 |
| TG (mg/dL)             | 4.85                 | 6.56  | 0.461 | 0.502 | —     | 14.71        | 13.23 | 0.269 | 0.065 | −0.99        | 6.40  | 0.878 | 0.465 | 2.99         | 6.94  | 0.668 | 0.534 | 11.49        | 8.23  | 0.167 | 0.662 | 11.49        | 8.23  | 0.167 | 0.662 |
| **Diabetic parameters**|                      |       |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |
| FG (mg/dL)             | 8.57                 | 1.93  | 0.000 | 0.527 | —     | 10.63        | 3.05  | 0.001 | 0.272 | 12.29        | 2.37  | 0.000 | 0.414 | 11.34        | 2.21  | 0.000 | 0.645 | 11.14        | 3.09  | 0.001 | 0.268 | 11.14        | 3.09  | 0.001 | 0.268 |
| HbA1c (%)              | 0.20                 | 0.03  | 0.000 | 0.326 | —     | 0.36         | 0.04  | 0.000 | 0.459 | 0.35         | 0.07  | 0.000 | 0.303 | −0.02         | 0.06  | 0.697 | 0.525 | 0.20         | 0.09  | 0.023 | 0.066 | 0.20         | 0.09  | 0.023 | 0.066 |
| FI (µU/mL)             | −0.44                | 0.83  | 0.000 | 0.080 | —     | −2.26        | 1.35  | 0.015 | 0.78  | 0.91         | 0.393 | 0.015 | 2.13 | 1.01        | 0.038 | 0.173 | 0.268 | 2.26         | 1.08  | 0.040 | 0.138 | 11.14        | 3.09  | 0.001 | 0.268 |
| HOMA-IR                | 0.17                 | 0.24  | 0.495 | 0.308 | −0.16 | 0.35         | 0.646 | 0.250 | 0.52 | 0.27         | 0.059 | 0.295 | 0.93 | 0.29        | 0.002 | 0.532 | 0.004 | 0.89 | 0.30        | 0.004 | 0.547 | —     | —     | —     | —     | —     |
| **Vital parameters**   |                      |       |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |               |       |       |       |
| SBP (mm Hg)            | −0.48                | 2.33  | 0.838 | 0.288 | —     | −0.70        | 2.75  | 0.799 | 0.277 | −4.28        | 2.65  | 0.110 | 0.374 | 5.34         | 3.32  | 0.113 | 0.351 | −1.01        | 3.63  | 0.782 | 0.273 | 5.34         | 3.32  | 0.113 | 0.351 |
| DBP (mm Hg)            | −0.23                | 1.35  | 0.864 | 0.249 | —     | 0.04         | 1.49  | 0.980 | 0.285 | −4.38        | 1.53  | 0.005 | 0.406 | 0.10         | 1.76  | 0.956 | 0.229 | −1.78        | 1.69  | 0.297 | 0.381 | 0.10         | 1.76  | 0.956 | 0.229 |

- Constants (β₀) and its SE are not shown and numbers are rounded to two decimals to improve readability; an extended version of the table can be found in appendix (online supplemental table S-1, online supplemental figure S-2, online supplemental table S-3).
- Bold p-values ≤0.05
- β, effect size for group; BMI, body mass index; DBP, diastolic blood pressure; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, Homeostasis Model Assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol; R², corrected R²; SBP, systolic blood pressure; TG, triglycerides; TOTAL-C, total cholesterol; WC, waist circumference.
The HLCP reached mainly women—as it is typical for health education interventions, but those men who did participate, benefited the most regarding weight change. This is in line with other studies that show higher weight loss in men,\(^{34}\)for example, due to gender-specific metabolic differences.\(^{34}\)

The diabetes risk profile in the IG did not improve. Notably, most participants (75%) in the IG had no increased diabetes risks at baseline and subgroup analyses showed that FG increased mainly in non-diabetics. In participants at higher risk, parameters tended to decrease. Yet, even when adjusting for risk group, sex and previous FG changes, the difference to the CG stayed significant, which was neither desirable nor expected, as lifestyle interventions are likely to improve diabetes risk parameters.\(^{35}\) The change of diabetes parameters was not mirrored in the improved outcome of other parameters, like weight and lipid profile, and can also not be explained by a change in medication. Possibly, factors that were not assessed, such as working conditions,\(^{36}\) had a relevant impact.

Notably, both groups reported a low average energy intake, indicating the long-known problem of under-reporting, especially in OW people.\(^{25}\) Technology-supported methods might help to improve dietary data assessment in the future.\(^{37}\)

As other intervention programmes before,\(^{1,14,30}\) the HLCP struggled to sustain the better risk profile in the longer term. Though weight loss was maintained throughout the study course of 2 years, other parameters did not improve that clearly.

Since we observed the biggest changes after the intensive phase of the HLCP, also regarding the higher adherence to the provegetarian food pattern, we suggest to intensify the alumni phase. An extension of digital and online measures\(^{38}\) may help participants to include these in their everyday life.

The intervention tended to have stronger and longer-term effects in participants at higher risk. Since we recruited from the general population, these high-risk subgroups were relatively small, which might have contributed to non-significance.\(^{28}\) Future programmes should aim for a larger sample of high-risk participants to test this hypothesis.

In the CG, some risk parameters (eg, HDL-C, TG or FG) improved as well. Possibly, the mere health checks have to be considered an intervention, since participants of the CG regularly received their results, due to ethical and motivational reasons, which can already initiate health behavioural change.\(^{39}\)

Limitations

Due to limited resources, the CG started with a delay of 6 months compared with IG and due to the nature of our real-world community approach, randomisation was not possible. However, IG and CG had similar baseline characteristics (except age, gender, BMI, HDL-C and energy intake) and we adjusted for those which were different between groups. Yet, the non-randomisation may have led to a bias due to the selection of particularly motivated participants.

Missing data occurred for blood parameters at baseline, which had to be taken on a different day than other parameters and only 90% (n=81) of the participants were available in the IG. Further disparities of sample sizes occurred due to participants’ personal matters, for example, poor venous access. Also, the sample sizes in IG and CG dropped within the study course of 24 months (similarly in both groups) by around 50%. However, we analysed all the available data to avoid loss of information and overestimation of efficiency which can occur in all-case analyses.\(^{40}\)

Our observations should be validated in a bigger cohort, as we divided subgroups (eg, sex) retrospectively and did not consider them when calculating the sample size.

CONCLUSION

Our study gives valuable insights into the effects of lifestyle interventions in communities as a real-world lab. The HLCP moderately reduced weight of the participants in the long term and slightly improved the risk profile for NCDs mostly in the short term and with regard to some, but not all, parameters. Modifications should be made to improve results with a lower educational status, and more participants with a high cardiometabolic risk should be recruited in future studies.

Acknowledgements We would like to thank the study participants, the local stakeholders involved, for example, city administration, medical practitioners and volunteers, Alwine Kraatz who took part in the investigation, Matthias Borowski, PhD for his statistical advice, our student helpers and the entire research group.

Contributors CA: guarantor of overall content, conceptualisation, methodology, validation, formal analysis, investigation, participant management, data assessment and curation, writing original draft, review and editing of the text, visualisation, project administration, funding acquisition. R-MK: participant management, data assessment and curation, review and editing. SH: data assessment and curation, review and editing of the text. CK: data assessment and curation, review and editing of the text. NS: participant management, data assessment and curation, review and editing of the text. D-KA: data assessment, review and editing of the text. KH: methodology, medical advice, review and editing of the text, supervision. RG: methodology, medical advice, review and editing of the text, supervision. HE: conceptualisation, methodology, investigation, review and editing of the text, project administration, supervision, funding acquisition.

Funding This work was conducted as part of the project ‘KRABE’ and was funded by EUREGIO within the INTERREG V A programme Deutschland-Niederland (ANBest INTERREG DE-NL) with the following grant number: 203018. We acknowledge support from the Open Access Publication Fund of the University of Muenster.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Westphalia-Lippe Medical Association and the Muenster University (Muenster, Germany; reference: 2017-105 f-S, approved 5 April 2017). All participants provided written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer reviewed.
peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use permits others to distribute, remix, adapt, build upon this work non-commercially.

ORCID iDs
Corinna Anand http://orcid.org/0000-0002-4314-9804
Ragna-Marie Kranz http://orcid.org/0000-0002-7191-9888

REFERENCES

1 Nyberg ST, Batty GD, Pentti J, et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. Lancet Public Health 2018;3:e490–7.
2 Hamer M, Kivimäki M, Gale CR, et al. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 587,109 adults in UK. Brain Behav Immun 2020;87:184–7.
3 Webb VL, Wadden TA. Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results. Gastroenterology 2015;127:1752–64.
4 Jayedi A, Softani S, Abdolshahi A, et al. Healthy and unhealthy dietary patterns and the risk of chronic disease: an umbrella review of meta-analyses of prospective cohort studies. Br J Nutr 2020;124:1134–44.
5 Morze J, Danielewicz A, Hoffmann G, et al. Diet quality as assessed by the healthy eating index, alternate healthy eating index, dietary approaches to stop hypertension score, and health outcomes: a second update of a systematic review and meta-analysis of cohort studies. J Acad Nutr Diet 2020;120:194–201.
6 Posadzki P, Pieper D, Bajpai R, et al. Exercise/physical activity and health outcomes: an overview of Cochrane systematic reviews. BMC Public Health 2020;20:1724.
7 Tomyiamma AJ. Stress and obesity. Ann Rev Psychol 2019;70:703–18.
8 O’Connor DB, Thayer JF, Vedhara K, Stress and health: a review of Psychobiological processes. Ann Rev Psychol 2021;72:663–88.
9 Cha E, Crowe JM, Braxter BJ, et al. Understanding how overweight and obese emerging adults make lifestyle choices. J Pediatr Nurs 2016;31:e230–3.
10 Yousaf O, Grunfeld EA, Hunter MS. A systematic review of the factors associated with delays in medical and psychological help-seeking among men. Health Psychol Rev 2015;9:264–76.
11 Lastrucci V, Lorni C, Caini S, et al. Health literacy as a mediator of the relationship between socioeconomic status and health: a cross-sectional study in a population-based sample in Florence. PLoS One 2019;14:e0227007.
12 Svendsen MT, Bak CK, Sørensen K, et al. Associations of health literacy with socioeconomic position, health risk behavior, and health status: a large national population-based survey among Danish adults. BMC Public Health 2020;20:565.
13 Wennehorst K, Mildenstein K, Saliger B, et al. A comprehensive lifestyle intervention to prevent type 2 diabetes and cardiovascular diseases: the German CHIPS trial. Prev Sci 2016;17:386–97.
14 Romanelli RJ, Sudat S, Huang Q, et al. Short-term weight trajectories and long-term weight outcomes from a lifestyle intervention in real-world clinical practice. Transl Behav Med 2020;10:1458–71.
15 Burgess E, Hassenm P, Pumpa KL. Determinants of adherence to lifestyle intervention in adults with obesity: a systematic review. Clin Obes 2017;7:123–35.
16 Renn O. Real-World Laboratories - the Road to Transdisciplinary Research? GAIA - Ecological Perspectives for Science and Society 2018:271.
17 Koeder C, Hahn A, Englert H. Effect of a 6-month controlled lifestyle intervention on common carotid intima-media thickness. J Nutr Health Aging 2021;25:869–87.
18 World Health Organisation (WHO). Physical status: the use and interpretation of anthropometry: report of a who expert Committee. Geneva: World Health Organisation, 1995.
19 National Heart Lung and Blood Institute. Management of blood cholesterol in adults: systematic evidence review from the cholesterol expert panel, 2013.
20 Petersmann A, Müller-Wieland D, Müller UA, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2019;127:S1–7.
21 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.
22 Tang Q, LU X, Song P, et al. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: developments in research and prospects for the future. Drug Discov Ther 2015;9:380–5.
23 Straßburg A, Eisinger-Watzi M, Krems C, et al. Comparison of food consumption and nutrient intake assessed with three dietary assessment methods: results of the German national nutrition survey II. Eur J Nutr 2019;58:193–210.
24 Martínez-González MA, Sánchez-Tabaí A, Corella D, et al. A provegetarian food pattern and reduction in total mortality in the Prevención Con Dieta Mediterránea (PREDIMED) study. Am J Clin Nutr 2014;100 Suppl 1:S205–8.
25 Schwarzer R, Sniehotta FF. On the assessment and analysis of variables in the health action process approach: conducting an investigation, 2003; 1–18. http://www.tu-berlin.de/gesund/hapa_web.pdf.
26 IPAQ Research Committee. Guidelines for data processing and analysis of the International physical activity questionnaire (IPAQ): short and long forms, 2005. Available: https://www.academia.edu/ S346814/Guidelines_for_Data_Processing_and_Analysis_of_the_International_Physical_Activity_Questionnaire_IPAQ_Short_and_Long_Forms_Contents [Accessed 1 Sep 2019].
27 Klein EM, Brähler E, Dreier M, et al. The German version of the Perceived Stress Scale - psychometric characteristics in a representative German community sample. BMC Psychiatry 2016;16:159.
28 Gaus W. Interpretation of Statistical Significance - Exploratory Versus Confirmative Testing in Clinical Trials, Epidemiological Studies, Meta-Analyses and Toxicological Screening (Using Ginkgo biloba as an Example), Clin Exp Pharmacol Pharmacotherapeutics 2015:030.
29 Wilson K. Obesity: lifestyle modification and behavior changes. FP Essent 2020;492:19–24.
30 Sun Y, You W, Almeida F, et al. The effectiveness and cost of lifestyle interventions including nutrition education for diabetes prevention: a systematic review and meta-analysis. J Acad Nutr Diet 2017;117:404–21.
31 Kahleova H, Fleeman R, Hlozkova A, et al. A plant-based diet in overweight individuals in a 16-week randomized clinical trial: metabolic benefits of plant protein. Nutr Diabetes 2018;8:58.
32 Johs DJ, Hartmann-Boyce J, Jebb SA, et al. Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons. J Acad Nutr Diet 2014;114:1557–68.
33 Christensen P, Meintert Lassen J, Westerterp-Plantenga M, et al. Men and women respond differently to rapid weight loss: metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (preview), Diabetes Obes Metab 2018;20:2840–51.
34 Williams RL, Wood LG, Cleary BS, et al. Effectiveness of weight loss interventions—is there a difference between men and women: a systematic review. Obes Rev 2015;16:171–86.
35 Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation 2016;133:187–225.
36 Ledda C, Cinà D, Matera S, et al. High HOMA-IR index in healthcare shift workers. Medicina 2019;55:186.
37 McClung HL, Pitemy LT, Shook RP, et al. Dietary intake and physical activity assessment: current tools, techniques, and technologies for use in adult populations. Am J Prev Med 2018;55:e93–104.
38 Van Rhoon L, Byrne M, Morrissey E, et al. A systematic review of the behaviour change techniques and digital features in technology-driven type 2 diabetes prevention interventions. Digit Health 2020;6:205520762094427.
39 Kang C, Kawamura A, Noguchi H. Benefits of knowing own health status: effects of health check-ups on health behaviours and labour participation. Appl Econ Lett 2021;28:926–31.
40 Jamshidian M, Mata M. Advances in Analysis of Mean and Covariance Structure when Data are Incomplete. In: Lee S-Y, ed. Handbook of latent variable and related models. 1st edn. Amsterdam: Elsevier, 2007: 21–44.
Table S-1 Multiple regression models for weight loss after 8 weeks, 6, 12, 18 and 24 months; residuals of all models normally distributed; all cases analysed

| WEIGHT CHANGE AFTER | β    | SE   | p-value |
|---------------------|------|------|---------|
| **8 WEEKS**\(^1\)   |      |      |         |
| constant (\(β_0\))  | -2.81| 1.04 | **0.003** |
| group (ref. intervention) | -1.79| 0.76 | **0.020** |
| sex (ref. male)      | -1.88| 0.50 | **0.000** |
| male-by-intervention group interaction | -1.99| 0.78 | **0.020** |
| overweight at baseline | -0.75| 0.35 | **0.028** |
| came without family  | -1.18| 0.48 | **0.006** |
| **6 MONTHS**\(^2\)   |      |      |         |
| constant (\(β_0\))  | -3.56| 1.51 | **0.020** |
| group (ref. intervention) | -1.15| 0.69 | 0.097   |
| lower education level | -0.85| 0.34 | **0.015** |
| university degree (ref. yes) | -1.99| 0.89 | **0.027** |
| **12 MONTHS**\(^3\) |      |      |         |
| constant (\(β_0\))  | -0.44| 0.37 | 0.365   |
| group (ref. intervention) | -0.64| 0.51 | 0.209   |
| university degree (ref. yes) | -0.96| 0.54 | **0.080** |
| **18 MONTHS**        |      |      |         |
| constant (\(β_0\))  | 3.78 | 1.24 | **0.003** |
| group (ref. intervention) | -0.31| 0.47 | 0.502   |
| university degree (ref. yes) | -1.02| 0.49 | **0.040** |
| overweight at baseline | -1.61| 0.65 | **0.016** |
| male-by-participating with/without family | -1.65| 0.52 | **0.002** |
| male-by-overweight at baseline interaction | -1.61| 0.68 | **0.020** |
| **24 MONTHS**        |      |      |         |
| constant (\(β_0\))  | 0.45 | 0.42 | 0.290   |
| group (ref. intervention) | 0.29 | 0.72 | 0.683   |
| university degree-by-intervention group interaction | -2.14| 1.16 | **0.069** |

β = effect size

\(^1\) n = 116, p < 0.001, corrected R² = 0.216, BS, adjusted for age, group-by-came with/without family interaction
\(^2\) n = 94, p < 0.001; corrected R² = 0.491, BS, adjusted for age, group-by-sex interaction, weight loss after 8 weeks
\(^3\) n = 84, p < 0.001; corrected R² = 0.535, FS, adjusted for age, group-by-sex interaction, weight loss after 8 weeks
\(^4\) n = 73, p < 0.001; corrected R² = 0.771, FS, adjusted for age, weight loss after 6 and 12 months
\(^5\) n = 66, p < 0.001; corrected R² = 0.696, FS, adjusted for weight loss after 18 months

ref. = reference
Figure S-2: Changes of Total-, LDL-, HDL-cholesterol (C), triglycerides (TG) and fasting glucose (FG) in intervention and control group and according to risk status at baseline (high risk: Total-C ≥ 200 mg/dl, LDL-C ≥ 130 mg/dl, HDL-C ≤ 40 and 45 for men and women, respectively, TG ≥ 150 mg/dl, FG ≥ 100 mg/dl. Changes of systolic and diastolic blood pressure (BP) in intervention and control group.
Table S-3: Change of anthropometric and blood parameters in the intervention and control group, including subgroup analyses.

|                        | INTERVENTION |                          | CONTROL |                          |
|------------------------|--------------|---------------------------|---------|---------------------------|
|                        | Change after |                          | Change after |
|                        | initial value| at baseline               | 10 weeks | 6 months | 12 months | 18 months | 24 months | initial value| 10 weeks | 6 months | 12 months | 18 months | 24 months |
| **ANTHROPOMETRICS**    |              |                          |         |           |           |           |           |              |         |           |           |           |           |
| weight (kg), mean ± SD | 90 (n=90)    | 64 (80)                  | 62 (50) | 50 (51)   | 51 (52)   | 52 (51)   | 52 (51)   | 36 (52)     | 36 (51)   | 33 (52)   | 26 (24)   | 26 (25)   | 26 (26)   |
| according to sex       |              |                          |         |           |           |           |           |              |         |           |           |           |           |
| men, n=21              | 21 (n=21)    | 17 (17)                  | 17 (13) | 17 (15)   | 15 (15)   | 15 (21)   | 15 (21)   | 15 (15)     | 18 (21)   | 18 (15)   | 12 (11)   | 11 (14)   | 11 (15)   |
| women, n=69            | 69 (n=69)    | 63 (47)                  | 45 (37) | 36 (36)   | 30 (30)   | 30 (21)   | 15 (14)   | 15 (15)     | 15 (15)   | 14 (15)   | 15 (15)   | 15 (15)   | 15 (15)   |
| according to “came with family” |          |                          |         |           |           |           |           |              |         |           |           |           |           |
| yes, n=26              | 26 (n=26)    | 22 (21)                  | 21 (19) | 19 (16)   | 14 (15)   | 15 (15)   | 7 (3)     | 10 (10)     | 10 (10)   | 7 (3)     | 3 (2)     | 3 (2)     | 3 (3)     |
| no, n=64               | 64 (n=64)    | 58 (43)                  | 43 (36) | 35 (36)   | 30 (30)   | 30 (27)   | 19 (23)   | 23 (23)     | 23 (23)   | 19 (23)   | 19 (19)   | 19 (19)   | 19 (19)   |
| according to education |              |                          |         |           |           |           |           |              |         |           |           |           |           |
| LSS, n=21              | 21 (n=21)    | 17 (12)                  | 12 (8)  | 8 (9)     | 9 (13)    | 13 (10)   | 10 (10)   | 10 (10)     | 10 (10)   | 10 (10)   | 10 (10)   | 10 (10)   | 10 (10)   |
| HSS, n=29              | 29 (n=29)    | 25 (22)                  | 21 (21) | 18 (18)   | 17 (17)   | 11 (11)   | 8 (8)     | 8 (8)       | 8 (8)     | 8 (8)     | 8 (8)     | 8 (8)     | 8 (8)     |
| HS, n=21               | 21 (n=21)    | 20 (18)                  | 16 (12) | 14 (14)   | 5 (5)     | 4 (4)     | 3 (3)     | 3 (2)       | 2 (2)     | 2 (2)     | 2 (2)     | 2 (2)     | 2 (2)     |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
|                | INTERVENTION | Control |
|----------------|--------------|---------|
|                | Change after | Change after |
|                | initial value | at baseline | 10 weeks | 6 months | 12 months | 18 months | 24 months | initial value | 10 weeks | 6 months | 12 months | 18 months | 24 months |
| no UD (comb.), n= 71 | 62 | 52 | 49 | 41 | 41 | 35 | 25 | 27 | 24 | 20 | 20 |
| UD, n= 19 | 18 | 12 | 13 | 9 | 10 | 14 | 11 | 9 | 9 | 6 | 6 |
| according to BMI (kg/m²) at baseline |
| NW: < 25 kg/m², n= 23 | 20 | 18 | 17 | 14 | 14 | 23 | 17 | 18 | 17 | 14 | 12 |
| OW/ OB (comb.), n= 67 | 60 | 46 | 45 | 36 | 37 | 28 | 19 | 18 | 16 | 12 | 14 |
| OW: ≥ 25 kg/m², n= 31 | 29 | 25 | 24 | 23 | 23 | 18 | 12 | 12 | 10 | 8 | 8 |
| OB I: 30-34.9 kg/m², n= 22 | 20 | 14 | 13 | 10 | 10 | 7 | 5 | 4 | 4 | 3 | 4 |
| OB II: 35-39.9 kg/m², n= 11 | 8 | 4 | 5 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| OB III: BMI > 40 kg/m², n= 3 | 3 | 3 | 3 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 |
| BMI (kg/m²), mean ± SD | 28.7 ± 5.4 | 0.5 ± 0.6 | 0.4 ± 1.1 | -0.8 ± 1.1 | 0.7 ± 1.3 | -0.6 ± 1.3 | 27.0 ± 6.5 | -0.1 ± 0.6 | -0.2 ± 0.7 | -0.2 ± 0.9 | -0.1 ± 1.0 | -0.4 ± 1.8 |
| WC (cm), mean ± SD | 90 | 78 | 64 | 62 | 49 | 51 | 52 | 36 | 36 | 33 | 26 | 26 |

According to sex
| men, n= | initial value at baseline | 6 weeks | 10 weeks | 12 months | 18 months | 24 months | initial value at baseline | 6 weeks | 10 weeks | 12 months | 18 months | 24 months |
|--------|--------------------------|---------|---------|-----------|-----------|-----------|--------------------------|---------|---------|-----------|-----------|-----------|
| 21     | 105.0 ± 13.0             | -0.5 ± 4.9 | 1.0 ± 6.0 | -0.4 ± 5.0 | -1.0 ± 5.5 | -1.1 ± 6.1 | 108.1 ± 16.8             | -1.4 ± 2.7 | -1.3 ± 2.3 | -0.3 ± 3.6 | -2.6 ± 3.0 | -1.8 ± 2.8 |
| 68     | 96.4 ± 13.3              | 0.5 ± 4.7 | -0.8 ± 5.4 | -1.8 ± 5.6 | -2.5 ± 5.6 | -3.2 ± 4.8 | 91.3 ± 13.9              | -1.9 ± 4.6 | -2.7 ± 4.5 | -0.3 ± 3.6 | -1.1 ± 3.2 | -5.4 ± 5.4 |
| according to risk at baseline (men) | low (> 102 cm), n= | 10 | 9 | 9 | 15 | 8 | 13 | 8 | 11 | 8 | 8 | 8 |
| 94.7 ± 4.6 | -0.8 ± 5.1 | -0.4 ± 5.0 | -1.7 ± 4.3 | -2.4 ± 5.1 | -2.4 ± 5.8 | 94.1 ± 5.0 | 0.1 ± 2.7 | -1.4 ± 2.8 | -1.2 ± 4.0 | -0.5 ± 3.1 | -1.7 ± 1.8 |
| elevated (≥ 102 cm), n= | 11 | 7 | 8 | 9 | 5 | 7 | 13 | 8 | 11 | 8 | 11 | 8 |
| 114.4 ± 10.7 | -0.2 ± 5.0 | 2.6 ± 7.0 | 0.8 ± 5.7 | 1.0 ± 5.8 | 0.3 ± 6.5 | 116.7 ± 15.6 | -2.7 ± 2.0 | -1.1 ± 2.0 | -1.6 ± 3.2 | -3.6 ± 2.6 | -1.8 ± 3.2 |
| according to risk at baseline (women) | low (> 88 cm), n= | 19 | 18 | 15 | 15 | 12 | 12 | 12 | 7 | 7 | 6 | 6 | 6 |
| 80.5 ± 4.7 | 0.4 ± 3.6 | -1.3 ± 5.1 | -0.3 ± 4.4 | -0.8 ± 3.6 | -2.8 ± 3.3 | 78.1 ± 6.3 | -1.8 ± 2.9 | -0.6 ± 3.3 | 1.4 ± 2.6 | -0.1 ± 2.6 | -2.9 ± 3.6 |
| elevated (≥ 88 cm), n= | 49 | 44 | 32 | 30 | 25 | 24 | 18 | 14 | 11 | 9 | 8 | 9 |
| 102.5 ± 10.0 | 0.5 ± 5.1 | -0.6 ± 5.6 | -2.6 ± 6.1 | -3.4 ± 6.3 | -3.4 ± 5.5 | 100.1 ± 9.9 | -2.0 ± 5.4 | -4.0 ± 4.8 | -1.5 ± 3.9 | -1.9 ± 3.5 | -7.1 ± 6.1 |

**BLOOD PARAMETERS**

| lipids | TC (mg/dl), mean ± SD, n= | initial value at baseline | 6 weeks | 10 weeks | 12 months | 18 months | 24 months | initial value at baseline | 6 weeks | 10 weeks | 12 months | 18 months | 24 months |
|--------|--------------------------|--------------------------|---------|---------|-----------|-----------|-----------|--------------------------|---------|---------|-----------|-----------|-----------|
| men, n= | 81 | 195.6 ± 33.4 | -9.3 ± 22.1 | -4.1 ± 44.9 | -6.3 ± 20.0 | -3.4 ± 17.4 | 1.7 ± 24.6 | 192.7 ± 46.2 | 12.5 ± 35.8 | 6.6 ± 26.9 | 6.7 ± 23.8 | 6.7 ± 23.8 | 4.4 ± 29.2 |
| women, n= | 64 | 199.3 ± 32.7 | -9.0 ± 23.2 | -1.3 ± 50.8 | -6.5 ± 19.6 | -4.5 ± 19.8 | 1.9 ± 26.6 | 196.5 ± 54.7 | 17.6 ± 44.0 | 6.1 ± 29.8 | 3.1 ± 26.4 | 8.8 ± 21.5 | -5.6 ± 19.6 |

Anand C, *et al.* BMJ 2022;0:e000340. doi: 10.1136/bmjnph-2021-000340
| according to risk at baseline | INTERVENTION | | CONTROL | |
|-----------------------------|--------------|------------------|------------------|
| low (< 200 mg/dl), n= 42    | initial value | 10 weeks | 6 months | 12 months | 18 months | 24 months | initial value | 10 weeks | 6 months | 12 months | 18 months | 24 months |
| Change after at baseline    | 170.2 ± 19.3 | -4.2 ± 15.9 | 2.4 ± 54.3 | -4.1 ± 20.3 | -3.2 ± 20.8 | 3.2 ± 27.1 | 159.4 ± 31.3 | 23.1 ± 39.3 | 13.0 ± 31.2 | 11.6 ± 25.9 | 3.3 ± 25.6 | 11.6 ± 34.4 |
| elevated (≥ 200 mg/dl), n= 39 | initial value | 223.0 ± 21.4 | -14.7 ± 26.3 | -11.3 ± 30.8 | -8.5 ± 19.7 | -3.5 ± 16.9 | -0.4 ± 21.3 | 233.1 ± 23.4 | -0.8 ± 26.5 | -1.9 ± 17.2 | -0.8 ± 18.8 | 3.4 ± 19.3 | -3.3 ± 20.9 |
| Change after at baseline    | 125.5 ± 35.6 | -6.0 ± 21.1 | -8.1 ± 22.3 | -4.7 ± 18.5 | 0.9 ± 16.1 | -0.3 ± 22.7 | 127.0 ± 41.5 | 12.4 ± 29.0 | 5.1 ± 22.5 | 6.3 ± 20.0 | 7.7 ± 22.1 | 4.3 ± 30.5 |
| LDL-C (mg/dl), mean ± SD, n= 79 | initial value | 122.7 ± 37.0 | -7.8 ± 15.9 | -10.2 ± 10.8 | -2.6 ± 19.3 | 2.8 ± 17.5 | -0.3 ± 17.5 | 124.1 ± 33.0 | 10.9 ± 18.0 | 7.8 ± 22.1 | 10.0 ± 20.4 | 0.1 ± 25.3 | 18.9 ± 35.7 |
| Change after at baseline    | 126.2 ± 35.4 | -5.5 ± 22.5 | -7.4 ± 25.0 | -5.4 ± 18.4 | -2.1 ± 15.7 | -0.3 ± 24.8 | 129.1 ± 47.0 | 13.5 ± 35.3 | 2.7 ± 23.3 | 1.8 ± 19.4 | 13.9 ± 17.8 | -7.1 ± 20.4 |
| according to sex            | men, n= 17   | initial value | 122.7 ± 37.0 | -7.8 ± 15.9 | -10.2 ± 10.8 | -2.6 ± 19.3 | 2.8 ± 17.5 | -0.3 ± 17.5 | 124.1 ± 33.0 | 10.9 ± 18.0 | 7.8 ± 22.1 | 10.0 ± 20.4 | 0.1 ± 25.3 | 18.9 ± 35.7 |
| Change after at baseline    | 122.7 ± 37.0 | -7.8 ± 15.9 | -10.2 ± 10.8 | -2.6 ± 19.3 | 2.8 ± 17.5 | -0.3 ± 17.5 | 124.1 ± 33.0 | 10.9 ± 18.0 | 7.8 ± 22.1 | 10.0 ± 20.4 | 0.1 ± 25.3 | 18.9 ± 35.7 |
| women, n= 62               | initial value | 124.4 ± 7.0  | -7.4 ± 18.9 | -4.2 ± 16.1 | 0.7 ± 14.5 | 0.0 ± 14.4 | 0.5 ± 17.0 | 146.7 ± 9.2  | 5.3 ± 12.8  | 0.3 ± 15.4 | -0.5 ± 21.2 | 0.9 ± 24.2 | 4.7 ± 10.8 |
| Change after at baseline    | 120.5 ± 6.4  | -7.1 ± 20.5 | -4.3 ± 24.8 | -2.5 ± 3.5 | 5.0 | -3.0 | 229.5 ± 40.3 | -26.0 ± 48.1 | -41.0 | - | - | -48.0 |
|                      | INTERVENTION |                      | CONTROL |
|----------------------|--------------|----------------------|---------|
|                      | initial value at baseline | 10 weeks | 6 months | 12 months | 18 months | 24 months | initial value at baseline | 10 weeks | 6 months | 12 months | 18 months | 24 months |
| according to risk at baseline |                        |         |         |           |           |          |                        |         |         |           |           |          |
| low (< 130 mg/dl), n= | 43            | 42       | 32       | 29        | 28        | 30        | 26            | 19       | 17       | 18         | 13         | 12         |
| moderate/ high (comb.; >130 mg/dl), n= | 36          | 29       | 23       | 25        | 23        | 22        | 25            | 27       | 24       | 21         | 19         | 17         |
| HDL-C (mg/dl), mean ± SD, n= | 80           | 64.6 ± 19.1 | -2.2 ± 7.1 | -3.0 ± 10.7 | 1.6 ± 6.2 | 3.4 ± 10.1 | 1.8 ± 8.6     | 56.5 ± 18.1 | 5.2 ± 10.7 | 1.7 ± 8.9 | 4.1 ± 9.9 | 0.7 ± 8.9 | -0.4 ± 10.0 |
| according to sex |                            |         |         |           |           |          |                        |         |         |           |           |          |
| men, n=              | 17            | 50.8 ± 14.7 | -2.1 ± 6.4 | -4.3 ± 9.2 | 1.5 ± 4.8 | 2.6 ± 3.8 | 0.7 ± 6.2     | 50.7 ± 18.4 | 2.1 ± 5.8 | -0.4 ± 7.0 | 3.3 ± 8.5 | 0.3 ± 8.6 | -1.7 ± 8.4 |
| women, n=            | 63            | 68.3 ± 18.6 | -2.2 ± 7.3 | -2.6 ± 11.2 | 1.7 ± 6.7 | 3.6 ± 11.4 | 2.2 ± 9.5     | 60.6 ± 17.1 | 7.5 ± 12.9 | 3.7 ± 10.2 | 5.0 ± 11.6 | 1.1 ± 9.5 | 0.6 ± 11.3 |
| according to risk at baseline (men) |                        |         |         |           |           |          |                        |         |         |           |           |          |
| low (> 40), n=       | 15            | 53.1 ± 14.1 | -2.4 ± 6.5 | -4.9 ± 9.2 | 1.3 ± 4.9 | 2.4 ± 4.0 | 0.7 ± 6.4     | 59.9 ± 15.2 | -0.4 ± 4.1 | -1.5 ± 7.6 | 1.9 ± 9.4 | -4.0 ± 8.2 | -7.3 ± 7.3 |
| elevated (≤ 40), n=  | 2             | 33.5 ± 0.7  | 3.0 ± 4.0 | 4.0      | 5.0      | 1.0      | 32.3 ± 5.7     | 7.6 ± 5.4 | 3.0 ± 3.2 | 7.0 ± 4.8 | 6.2 ± 5.2 | 5.0 ± 2.8 |
| according to risk at baseline (women) |                        |         |         |           |           |          |                        |         |         |           |           |          |
| low (> 45), n=       | 60            | 69.7 ± 17.8 | -2.2 ± 7.4 | -2.6 ± 11.4 | 1.8 ± 6.8 | 3.6 ± 11.6 | 2.3 ± 9.6     | 66.7 ± 13.0 | 3.4 ± 9.8 | 0.7 ± 5.8 | 4.3 ± 12.1 | -0.9 ± 8.6 | -2.6 ± 6.0 |
|                | INTERVENTION |                        | CONTROL |                        |
|----------------|--------------|------------------------|---------|------------------------|
|                | Change after |                        | Change after |                        |
|                | initial value at baseline | 10 weeks | 6 months | 12 months | 18 months | 24 months | initial value at baseline | 10 weeks | 6 months | 12 months | 18 months | 24 months |
| elevated (≥ 45), n= | 3 | 2 | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 2 | 2 | 2 |
| TG (mg/dl), mean ± SD, n= | 80 | 76 | 57 | 55 | 49 | 31 | 51 | 38 | 35 | 33 | 27 | 25 |
| according to sex | | | | | | | | | | | | |
| men, n= | 17 | 15 | 14 | 12 | 15 | 21 | 16 | 17 | 18 | 10 | 11 | |
| 120.7 ± 74.7 | -11.5 ± 34.1 | -11.2 ± 40.8 | -19.0 ± 39.4 | -9.8 ± 28.1 | 0.1 ± 61.9 | 157.5 ± 95.8 | -35.9 ± 72.8 | -20.7 ± 42.6 | -15.6 ± 55.1 | -15.7 ± 48.9 | -33.9 ± 93.7 | |
| women, n= | 63 | 61 | 43 | 41 | 37 | 36 | 30 | 22 | 18 | 15 | 15 | 14 |
| 121.5 ± 68.2 | -15.9 ± 42.2 | -0.2 ± 78.9 | -17.8 ± 31.5 | -12.4 ± 41.0 | -20.8 ± 47.9 | 102.2 ± 47.1 | -10.4 ± 41.2 | -15.1 ± 39.1 | -17.5 ± 35.1 | -12.4 ± 49.1 | -17.1 ± 40.4 | |
| according to risk at baseline | | | | | | | | | | | | |
| low (< 150 mg/dl), n= | 63 | 60 | 45 | 45 | 40 | 42 | 40 | 31 | 29 | 26 | 22 | 20 |
| 92.0 ± 28.8 | -3.2 ± 22.9 | 0.5 ± 29.4 | -9.0 ± 23.1 | 0.4 ± 26.9 | -0.2 ± 38.8 | 94.7 ± 29.9 | -4.3 ± 27.1 | -5.1 ± 27.3 | 1.0 ± 28.0 | 3.7 ± 29.9 | -0.1 ± 23.9 | |
| elevated (≥ 150 mg/dl), n= | 17 | 16 | 12 | 10 | 9 | 9 | 11 | 7 | 6 | 7 | 5 | 5 |
| 229.4 ± 69.0 | -59.4 ± 59.3 | -13.9 ± 149.1 | -59.2 ± 41.8 | -65.6 ± 33.5 | -82.1 ± 58.2 | 235.1 ± 89.9 | -95.7 ± 92.5 | -79.2 ± 37.5 | -81.4 ± 44.5 | -91.2 ± 34.1 | -122.2 ± 100.3 | |
| diabetic parameters | | | | | | | | | | | | |
| FG (mg/dl), mean ± SD, n= | 81 | | | | | | | | | | | |
| 94.8 ± 14.9 | -0.1 ± 8.7 | 3.8 ± 13.1 | 7.1 ± 9.8 | 7.1 ± 9.6 | 8.0 ± 10.2 | 97.0 ± 26.0 | -7.3 ± 19.2 | -5.8 ± 17.2 | -5.7 ± 13.9 | -4.2 ± 18.8 | -2.2 ± 18.3 | |
| according to sex | | | | | | | | | | | | |
| men, n= | 17 | 15 | 14 | 14 | 12 | 15 | 21 | 16 | 17 | 18 | 12 | 11 |
| 95.4 ± 13.0 | -2.1 ± 9.8 | 1.1 ± 10.4 | 6.5 ± 9.2 | 6.7 ± 6.7 | 10.2 ± 10.0 | 109.2 ± 25.8 | -14.8 ± 13.9 | -10.6 ± 15.5 | -7.1 ± 16.2 | -9.3 ± 19.8 | -6.4 ± 24.7 | |
| women, n= | 64 | 61 | 43 | 41 | 37 | 36 | 30 | 22 | 18 | 15 | 15 | 14 |
### HbA1c (%) at Baseline and Change Over Time

|                   | Intervention |                      | Control |                      |
|-------------------|--------------|-----------------------|---------|-----------------------|
|                   | Change after |
|                   | at baseline  | 10 weeks | 6 months | 12 months | 18 months | 24 months | initial value at baseline | 10 weeks | 6 months | 12 months | 18 months | 24 months |
|                   |              |          |          |           |           |           |                          |           |           |           |           |           |
| No diabetes (< 5.7 %), n= |             | 66       | 63       | 47        | 45        | 43        | 42         | 7.6 ± 12               | -0.2 ± 0.2| 0.4 ± 0.4| 0.9 ± 1.3| -1.4 ± 0.9| 0.5 ± 1.3 |
| Pre-diabetes (5.7 - 6.4 %), n= |             | 11       | 10       | 7         | 8         | 4         | 6          | 5.9 ± 0.2              | 0.0 ± 0.1| 0.1 ± 0.2| 0.2 ± 0.2| 0.2 ± 0.2| 0.3 ± 0.4 |
| Diabetes (≥ 6.5 %), n= |             | 3        | 3        | 3         | 2         | 2         | 2          | 7.6 ± 1.2              | -0.2 ± 0.2| 0.4 ± 0.4| 0.9 ± 1.3| -1.4 ± 0.9| 0.5 ± 1.3 |
|                   | according to risk at baseline |             |          |           |           |           |                          |           |           |           |           |           |
| No diabetes (< 100 mg/dl), n= |             | 61       | 58       | 45        | 44        | 40        | 42         | 94.7 ± 15.5            | -0.6 ± 8.4| 4.6 ± 13.9| 7.3 ± 10.1| 7.2 ± 10.5| 7.0 ± 10.2 |
| Pre-diabetes (100-125 mg/dl), n= |             | 17       | 15       | 10        | 10        | 7         | 7          | 88.4 ± 6.7             | 0.7 ± 8.8| 3.0 ± 10.9| 7.9 ± 8.4| 8.6 ± 7.4| 7.8 ± 7.3 |
| Diabetes (≥ 126 mg/dl), n= |             | 3        | 3        | 2         | 1         | 2         | 2          | 105.7 ± 18.5           | -0.8 ± 13.9| 44.0 ± 0.0| 2.6 ± 9.4| 5.3 ± 12.5| 21.0 ± 41.0 |
|                   | according to sex |             |          |           |           |           |                          |           |           |           |           |           |
| Men, n= |             | 17       | 15       | 14        | 14        | 12        | 14         | 5.4 ± 0.6             | 0.1 ± 0.2| 0.2 ± 0.2| 0.2 ± 0.3| 0.1 ± 0.4| 0.2 ± 0.3 |
| Women, n= |             | 63       | 61       | 43        | 41        | 37        | 36         | 5.4 ± 0.6             | 0.1 ± 0.2| 0.2 ± 0.2| 0.3 ± 0.4| 0.0 ± 0.4| 0.2 ± 0.3 |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information included in this article. This work is protected by copyright. © BMJ Publishing Group Limited. For permission to reuse any part of this article, please contact the copyright holder.
|                  | INTERVENTION |                   | CONTROL |                   |
|------------------|--------------|-------------------|---------|-------------------|
|                  | initial value| change after      | initial value| change after      |
|                  | at baseline  | after 10 weeks    | at baseline| after 10 weeks    |
|                  |             |                   |         |                   |
|                  |             |                   |         |                   |
|                  |             |                   |         |                   |
|                  |             |                   |         |                   |
|                  |             |                   |         |                   |
| F1 (µU/ml), mean ± SD, n= | 76 | 10.0 ± 6.2         | 51   | 11.0 ± 8.3         |
| according to sex | men, n=     | 16                | 14    | 11.0 ± 8.3         |
|                  |             | 9.7 ± 5.7         | 14    | 12.0 ± 6.4         |
|                  | women, n=   | 60                | 59    | 13.0 ± 6.4         |
|                  |             | 10.1 ± 6.3        | 42    | 14.0 ± 6.4         |
| HOMA-IR, mean ± SD, n= | 76 | 2.4 ± 1.7         | 51   | 2.8 ± 2.9          |
| according to sex | men, n=     | 16                | 14    | 2.8 ± 2.9          |
|                  |             | 2.4 ± 1.7         | 14    | 2.1 ± 2.4          |
|                  | women, n=   | 60                | 59    | 2.1 ± 2.4          |
| according to risk at baseline | normal insulin sensitivity (< 2.5), n= | 49 | 1.4 ± 0.6         | 29   | 1.4 ± 0.6         |
|                  | impaired insulin sensitivity (≥ 2.5), n= | 27 | 4.3 ± 1.6         | 4.8 ± 3.6 |
| VITAL PARAMETERS | SBP (mmHg), mean ± SD, n= | 89 | 51   |
|                  | INTERVENTION | CONTROL |
|------------------|-------------|---------|
|                  | Change after | Change after |
|                  | initial value | at baseline | initial value | at baseline |
|                  | 10 weeks | 6 months | 12 months | 18 months | 24 months | 10 weeks | 6 months | 12 months | 18 months | 24 months |
| change after initial value | 135.9 ± 19.7 | -6.5 ± 13.3 | -2.4 ± 13.5 | -7.6 ± 14.0 | -6.1 ± 16.0 | -6.0 ± 17.5 | 130.8 ± 19.9 | -3.0 ± 14.8 | 0.9 ± 16.1 | 0.0 ± 16.1 | 8.7 ± 18.0 | -1.3 ± 16.7 |
| according to sex | men, n= 21 | 17 | 17 | 17 | 13 | 15 | 21 | 15 | 18 | 18 | 12 | 11 |
|                  | 137.8 ± 20.3 | -4.6 ± 14.4 | -2.3 ± 10.3 | -8.1 ± 14.4 | -6.2 ± 14.9 | -1.5 ± 16.5 | 142.2 ± 17.9 | -3.3 ± 17.1 | 0.0 ± 18.6 | 1.3 ± 17.0 | -14.8 ± 22.4 | -0.7 ± 16.6 |
|                  | women, n= 68 | 64 | 47 | 45 | 37 | 36 | 30 | 21 | 18 | 15 | 14 | 15 |
|                  | 135.3 ± 19.7 | -7.0 ± 13.1 | 2-4 ± 14.6 | -7.5 ± 14.0 | -6.1 ± 16.6 | -7.9 ± 17.7 | 142.9 ± 17.3 | -2.8 ± 13.4 | 1.7 ± 13.5 | -1.5 ± 15.3 | -3.5 ± 15.3 | -3.1 ± 17.3 |
| according to risk at baseline | normal (< 120 mmHg), n= 19 | 17 | 16 | 13 | 14 | 12 | 15 | 8 | 8 | 5 | 5 | 5 |
|                  | 110.9 ± 8.3 | -4.1 ± 11.9 | 6.4 ± 12.1 | 7.8 ± 11.8 | 3.9 ± 14.1 | 10.0 ± 15.2 | 108.1 ± 6.9 | 6.9 ± 16.4 | 10.9 ± 13.0 | 14.8 ± 14.6 | 6.8 ± 113.9 | 14.5 ± 18.8 |
|                  | elevated (≥ 120 – 129 mmHg), n= 70 | 64 | 48 | 49 | 36 | 39 | 36 | 28 | 28 | 28 | 21 | 20 |
|                  | 142.7 ± 16.1 | 9.3 ± 12.3 | 5.3 ± 12.8 | 11.8 ± 11.4 | -10.0 ± 16.1 | -11.0 ± 15.1 | 140.3 ± 15.2 | 5.8 ± 13.3 | -2.0 ± 15.9 | -2.6 ± 15.0 | -12.4 ± 17.3 | -12.1 ± 13.0 |
| DBP (mmHg), mean ± SD, n= | | | | | | | | | | | | |
| according to sex | men, n= 21 | 17 | 17 | 17 | 13 | 15 | 21 | 15 | 18 | 18 | 12 | 11 |
|                  | 84.2 ± 11.4 | -1.9 ± 8.1 | -1.2 ± 8.3 | -3.1 ± 10.2 | -4.2 ± 6.9 | -1.9 ± 5.4 | 82.2 ± 7.8 | 2.7 ± 6.6 | 2.0 ± 6.0 | 3.2 ± 8.1 | -3.1 ± 8.1 | 1.7 ± 10.0 |
|                  | women, n= 68 | 64 | 47 | 45 | 37 | 36 | 30 | 21 | 18 | 15 | 14 | 15 |
|                  | 87.0 ± 11.5 | -2.1 ± 7.9 | -1.7 ± 7.4 | -8.3 ± 6.5 | -7.4 ± 8.0 | -8.4 ± 8.4 | 79.7 ± 9.5 | -1.2 ± 7.2 | -2.0 ± 10.8 | -2.7 ± 8.2 | -5.1 ± 8.4 | -3.8 ± 6.5 |
| according to risk at baseline | normal (< 80 mmHg), n= 25 | 21 | 18 | 17 | 15 | 15 | 20 | 11 | 14 | 11 | 10 | 10 |
|                  | 73.6 ± 4.6 | 0.5 ± 4.3 | 2.0 ± 4.6 | -1.7 ± 5.9 | -3.0 ± 4.6 | -1.1 ± 5.6 | 72.5 ± 5.0 | 3.1 ± 6.6 | 4.9 ± 5.1 | 5.0 ± 6.8 | -0.1 ± 6.1 | 1.8 ± 4.8 |
|                  | elevated (≥ 80 mmHg), n= 64 | 60 | 46 | 45 | 35 | 36 | 31 | 25 | 22 | 22 | 16 | 16 |
|                  | **INTERVENTION** |                  |                  |
|------------------|------------------|------------------|------------------|
|                  | **initial value** | **Change after** | **CONTROL**     |
|                  | at baseline      | 10 weeks         | 6 months         | 12 months        | 18 months        | 24 months        |
|                  |                  |                  |                  |                  |                  |                  |
|                  |                  | 91.3 ± 9.3       | -3.0 ± 8.6       | -3.0 ± 7.6       | -8.8 ± 7.7       | -8.1 ± 8.4       | -8.8 ± 8.1       | 86.1 ± 6.2       | -0.7 ± 7.2       | -1.7 ± 9.6       | -1.7 ± 8.6       | -6.8 ± 8.3       | -3.5 ± 9.7       |
|                  |                  | §§               | *               | §§              | *§§              | §§              | §§              | §§              | §§              | §§              | §§              | §§              |
|                  | initial value    |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
|                  | at baseline      |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
|                  |                  | 86.1 ± 6.2       | -0.7 ± 7.2       | -1.7 ± 9.6       | -1.7 ± 8.6       | -6.8 ± 8.3       | -3.5 ± 9.7       |                  |                  |                  |                  |                  |

**difference to baseline: p < 0.001 (within group comparison), * difference to baseline: p < 0.05 (within group comparison), § difference to control group: p < 0.001 (between group comparison), §§ difference to control group: p < 0.05 (between group comparison), § difference to intervention group: p < 0.001, §§ difference to intervention group: p < 0.05, § difference to higher secondary school/ to no uni degree: p < 0.05, § difference to normal weight and obesity I: p < 0.05, § difference to obesity I and obesity III: p < 0.05, § difference to intervention group: p < 0.05, §§ difference to low risk group: p < 0.001, §§ difference to low risk group: p < 0.05, § difference to moderate risk group: p < 0.05, § difference to no-diabetes risk group: p < 0.05

LSS =lower secondary school, HSS =higher secondary school, HS =high school, UD =university degree, comb. = sub groups combined, BMI = Body Mass Index, NW = normal weight ; OW = overweight ; OB = obesity ; WC =waist circumference, TC =total cholesterol, LDL-C =low density lipoprotein cholesterol, HDL-C =high density lipoprotein cholesterol, TG =triglycerides, FG =fasting glucose, FI =fasting insulin, HOMA-IR =Homeostasis Model Assessment-insulin resistance, SBP =systolic blood pressure, DBP =diastolic blood pressure